Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | DBH | P09172 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36980 | 0.80 | MEP1B (0.44) | MEP1BDBHESR1ESR2ERN1 | |
| SCHEMBL14421368 | 0.80 | PTGS1 (0.45) | MEP1BDBHESR1ESR2 | |
| SCHEMBL391375 | 0.80 | ACHE (0.46) | ACHEKDM4ECASP6CYP4F2CYP4A11 | |
| SCHEMBL523766 | 0.78 | ACHE (0.43) | ACHEKDM4ECASP6CYP4F2CYP4A11 | |
| SCHEMBL68262 | 0.77 | ACHE (0.55) | ACHEKDM4ECASP6TSHR | |
| SCHEMBL31296199 | 0.76 | TTR (0.46) | KDM4ECASP6 | |
| SCHEMBL6302839 | 0.76 | MEP1B (0.41) | MEP1BDBH | |
| SCHEMBL6124950 | 0.76 | MEP1B (0.41) | KDM4EMEP1BDBH | |
| SCHEMBL855473 | 0.76 | ACHE (0.42) | ACHEKDM4ECASP6CYP4F2CYP4A11 | |
| SCHEMBL6167933 | 0.76 | MEP1B (0.46) | MEP1BDBHESR1ESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497428-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-12-16 | — | — | US | disclosed |
| US-20230416460-A1 | COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED PRODUCT, AND LAMINATED SUBSTRATE | TDK CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| CN-116490355-A | Compound, resin composition, resin sheet, resin cured product, and laminated substrate | TDK株式会社 | 2023-07-25 | — | — | CN | disclosed |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| WO-2022209495-A1 | COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED OBJECT, AND LAMINATED SUBSTRATE | TDK株式会社 | 2022-10-06 | — | — | WO | disclosed |
| US-20210380624-A1 | GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-12-09 | — | — | US | disclosed |
| CN-113366007-A | Galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2021-03-25 | — | — | US | disclosed |
| EP-3765446-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | AXXAM S.p.A. (IT) | 2021-01-20 | — | — | EP | disclosed |
| CN-111868035-A | Substituted pyrazole FFA4/GPR120 receptor agonists | 阿克萨姆股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020078808-A1 | GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019175152-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | AXXAM S.P.A. (IT) | 2019-09-19 | — | — | WO | disclosed |
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-6211328-B1 | IN PRESENCE OF AN ACID | GUN EI CHEMICAL INDUSTRY CO., LTD (JP) | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | FFAR4, FFAR3, FFAR1 | ACHE 4485/4885KDM4E 3733/4885CASP6 3595/4885 |
| US-20210380624-A1 | GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | ACHE 2494/4885KDM4E 4680/4885CASP6 2244/4885 |
| US-12497428-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | ACHE 2494/4885KDM4E 4680/4885CASP6 2244/4885 |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | FFAR4, FFAR3, FFAR1 | ACHE 4485/4885KDM4E 3733/4885CASP6 3595/4885 |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | ACHE 2031/4885KDM4E 1277/4885CASP6 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.